AI Article Synopsis
- - Metabolic-associated fatty liver disease (MAFLD) is now the leading cause of chronic liver disease in children and adolescents worldwide.
- - While liver biopsy is the traditional method for diagnosis, new noninvasive techniques like velocity controlled transient elastography are being used to assess liver fibrosis.
- - Although research on genetic treatment options is still in progress, lifestyle modifications and weight loss remain the primary approaches to managing MAFLD in pediatric patients.
Article Abstract
Metabolic-associated fatty liver disease (MAFLD) has become the most common cause for chronic liver disease among children and adolescents globally. Although liver biopsy remains the gold standard for diagnosis, emerging technology, like velocity controlled transient elastography, a noninvasive method, is being utilized to evaluate degree of fibrosis in these patients. The discovery of multiple gene polymorphisms has brought new hope for possible treatment targets. However, this research is still ongoing, making lifestyle changes and weight reduction the current mainstay of treatment. This review briefly reviews the most recent data regarding the epidemiology, pathophysiology, diagnostic modalities, and treatment of pediatric MAFLD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ecl.2023.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!